A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum.

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Fluorouracil; Folinic acid; Oxaliplatin; Vatalanib
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CONFIRM-2
  • Sponsors Novartis
  • Most Recent Events

    • 04 Apr 2011 Results published in the Journal of Clinical Oncology.
    • 04 Apr 2011 Primary endpoint 'Overall-survival' has not been met, based on results published in the Journal of Clinical Oncology: official journal of the American Society of Clinical Oncology.
    • 03 Feb 2010 Official Title amended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top